Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Sales

Cellebrite DI (CLBT) EBITDA Margin (2020 - 2025)

Historic EBITDA Margin for Cellebrite DI (CLBT) over the last 6 years, with Q4 2025 value amounting to 16.32%.

  • Cellebrite DI's EBITDA Margin fell 28800.0% to 16.32% in Q4 2025 from the same period last year, while for Dec 2025 it was 16.49%, marking a year-over-year decrease of 168800.0%. This contributed to the annual value of 16.49% for FY2025, which is 867800.0% up from last year.
  • According to the latest figures from Q4 2025, Cellebrite DI's EBITDA Margin is 16.32%, which was down 28800.0% from 15.88% recorded in Q3 2025.
  • In the past 5 years, Cellebrite DI's EBITDA Margin registered a high of 194.58% during Q3 2024, and its lowest value of 79.18% during Q1 2024.
  • Moreover, its 5-year median value for EBITDA Margin was 9.91% (2022), whereas its average is 16.04%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first skyrocketed by 1858200bps in 2024, then crashed by -1787100bps in 2025.
  • Quarter analysis of 5 years shows Cellebrite DI's EBITDA Margin stood at 6.34% in 2021, then surged by 74bps to 11.06% in 2022, then tumbled by -236bps to 15.04% in 2023, then surged by 228bps to 19.2% in 2024, then fell by -15bps to 16.32% in 2025.
  • Its EBITDA Margin stands at 16.32% for Q4 2025, versus 15.88% for Q3 2025 and 18.74% for Q2 2025.